AR036056A1 - Formulaciones de lactonas y metodos de uso de las mismas - Google Patents
Formulaciones de lactonas y metodos de uso de las mismasInfo
- Publication number
- AR036056A1 AR036056A1 ARP020102236A ARP020102236A AR036056A1 AR 036056 A1 AR036056 A1 AR 036056A1 AR P020102236 A ARP020102236 A AR P020102236A AR P020102236 A ARP020102236 A AR P020102236A AR 036056 A1 AR036056 A1 AR 036056A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- cyclic
- phosphonyl
- aroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos de las fórmulas (1) y (2) que tienen una estructura lactona y un grupo metileno en la posición alfa de la estructura lactona. Se proveen compuestos aislados definidos por una de las estructuras mencionadas, donde R1-R7 independientemente entre sí o R3-R6 en su conjunto son un átomo de hidrógeno o un grupo o porción seleccionado del grupo formado por un grupo alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, fenilo, fenilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, halo, haloalquilo, hidroxilo, alcoxi, alcoxi sustituido, fenoxi, fenoxi sustituido, aroxi, aroxi sustituido, alquiltio, alquiltio sustituido, feniltio, feniltio sustituido, ariltio, ariltio sustituido, ciano, isociano, isociano sustituido, carbonilo, carbonilo sustituido, carboxilo, carboxilo sustituido, amina, amina sustituida, amida, amida sustituida, sulfonilo, sulfonilo sustituido, ácido sulfónico, fosforilo, fosforilo sustituido, fosfonilo, fosfonilo sustituido, poliarilo, poliarilo sustituido, un grupo cíclico C1-20, un grupo cíclico C1-20 sustituido, un grupo heterocíclico, un grupo heterocíclico sustituido, un aminoácido, un péptido y un polipéptido; Z es un heteroátomo seleccionado del grupo formado por oxígeno, azufre y nitrógeno en la forma de estructuras lineales, ramificadas o cíclicas; Z' es un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxilo, o un grupo orgánico C1-8, que incluye un heteroátomo seleccionado del grupo formado por oxígeno, azufre y nitrógeno en la forma de estructuras lineales, ramificadas o cíclicas; y X es un heteroátomo seleccionado del grupo formado por oxígeno, azufre y nitrógeno en la forma de estructuras lineales, ramificadas o cíclicas, o una lactona aislada definida por la estructura (3) donde: R1-R9 independientemente entre sí o R5 y R6 en su conjunto pueden ser un átomo de hidrógeno o cualquier otro grupo o porción seleccionado del grupo formado por un grupo alquilo, fenilo, fenilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, halo, haloalquilo, hidroxilo, alcoxi, alcoxi sustituido, fenoxi, fenoxi sustituido, aroxi, aroxi sustituido, alquiltio, alquiltio sustituido, feniltio, feniltio sustituido, ariltio, ariltio sustituido, ciano, isociano, isociano sustituido, carbonilo, carbonilo sustituido, carboxilo, carboxilo sustituido, amina, amina sustituida, amida, amida sustituida, sulfonilo, sulfonilo sustituido, ácido sulfónico, fosforilo, fosforilo sustituido, fosfonilo, fosfonilo sustituido, poliarilo, poliarilo sustituido, un grupo cíclico C1-20, un grupo cíclico C1-20 sustituido, un grupo heterocíclico, un grupo heterocíclico sustituido, un aminoácido, un péptido y un polipéptido; Y1, Y2 e Y3 independientemente entre sí o Y1 e Y2 en su conjunto pueden ser un átomo de hidrógeno o cualquier otro grupo o porción seleccionado del grupo formado por un grupo alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, fenilo, fenilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, halo, hidroxilo, alcoxi, alcoxi sustituido, fenoxi, fenoxi sustituido, aroxi, aroxi sustituido, alquiltio, alquiltio sustituido, feniltio, feniltio sustituido, ariltio, ariltio sustituido, ciano, isociano, isociano sustituido, carbonilo, carbonilo sustituido, carboxilo, carboxilo sustituido, amina, amina sustituida, amida, amida sustituida, sulfonilo, sulfonilo sustituido, ácido sulfónico, fosforilo, fosforilo sustituido, fosfonilo, fosfonilo sustituido, poliarilo, poliarilo sustituido, un grupo cíclico C1-20, un grupo cíclico C1-20 sustituido, un grupo heterocíclico, un grupo heterocíclico sustituido, un aminoácido, un péptido y un polipéptido; Z es un heteroátomo seleccionado del grupo formado por oxígeno, azufre y nitrógeno en la forma de estructuras lineales, ramificadas o cíclicas; X es un heteroátomo seleccionado del grupo formado por oxígeno, azufre y nitrógeno en la forma de estructuras lineales, ramificadas o cíclicas. Los compuestos lactona se pueden hacer reaccionar con un agente nucleofílico para abrir el anillo lactona en un compuesto de fórmula (2). La lactona de la fórmula(1), y los derivados funcionales de la misma, fue aislada de Secundaca virgata. Los compuestos purificados han demostrado actividad en ensayos destinados a determinar actividades antibacterianas y antifúngicas y para el tratamiento de trastornos proliferativos, tal como cáncer. Métodos para utilizar y preparar los compuestos son también divulgados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29787501P | 2001-06-13 | 2001-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR036056A1 true AR036056A1 (es) | 2004-08-04 |
Family
ID=23148076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102236A AR036056A1 (es) | 2001-06-13 | 2002-06-13 | Formulaciones de lactonas y metodos de uso de las mismas |
Country Status (21)
Country | Link |
---|---|
US (3) | US6900242B2 (es) |
EP (1) | EP1406895B1 (es) |
JP (1) | JP2005500289A (es) |
KR (1) | KR20040030676A (es) |
AR (1) | AR036056A1 (es) |
AT (1) | ATE406367T1 (es) |
AU (1) | AU2002306150B2 (es) |
BR (1) | BR0210432A (es) |
CA (1) | CA2450660C (es) |
CO (1) | CO5550429A2 (es) |
CY (1) | CY1108590T1 (es) |
DE (1) | DE60228576D1 (es) |
DK (1) | DK1406895T3 (es) |
ES (1) | ES2315365T3 (es) |
IL (3) | IL159296A0 (es) |
MX (1) | MXPA03011554A (es) |
PT (1) | PT1406895E (es) |
RS (1) | RS52139B (es) |
UY (1) | UY27334A1 (es) |
WO (1) | WO2002100854A1 (es) |
ZA (1) | ZA200400208B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL159296A0 (en) * | 2001-06-13 | 2004-06-01 | Magnachem Int Lab Inc | Lactone formulations and method of use |
US8188145B2 (en) | 2002-06-12 | 2012-05-29 | Magnachem International Laboratories, Inc. | Synthetic lactone formulations and method of use |
EP1562930A4 (en) * | 2002-11-05 | 2008-12-10 | Magnachem Int Lab Inc | SYNTHETIC LACTONE FORMULATIONS AND METHOD OF USE |
US20050045197A1 (en) * | 2003-08-28 | 2005-03-03 | Gelder Steven K. | Multiple drug delivery system & method |
MX2011004331A (es) * | 2008-10-24 | 2011-09-21 | Magnachem Int Lab Inc | Metodo para busqueda de compuestos que interactuan selectivamente con rad9. |
CN103099901B (zh) * | 2013-01-26 | 2014-07-30 | 张红 | 一种治疗子宫内膜移位症的中药灌肠剂 |
KR101988479B1 (ko) * | 2017-10-11 | 2019-09-24 | (주)휴럼 | 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2624723A (en) * | 1947-03-03 | 1953-01-06 | Allied Chem & Dye Corp | Lactone derivatives and method of making |
US2624732A (en) * | 1950-05-10 | 1953-01-06 | Burroughs Wellcome Co | Preparation of 5-benzyl-2,4-diaminopyrimidines |
US3203953A (en) * | 1963-01-18 | 1965-08-31 | Ciba Geigy Corp | Lactone obtained from helenium sp. and derivatives thereof |
US3210377A (en) * | 1963-06-05 | 1965-10-05 | Olin Mathieson | Gamma lactones |
US4001425A (en) * | 1974-04-17 | 1977-01-04 | E. I. Du Pont De Nemours And Company | Methods of treating hypertension and pharmaceutical compositions comprising 1-tertiary-alkyl-3-(substituted furyl)ureas as antihypertensive agents |
JPS5111173B2 (es) * | 1974-04-25 | 1976-04-09 | ||
JPS51125722A (en) | 1975-01-13 | 1976-11-02 | Sumitomo Chem Co Ltd | Germicides for industry and their preparation |
JPS597713B2 (ja) | 1977-12-19 | 1984-02-20 | 三井東圧化学株式会社 | 新規γ↓−ブチロラクトン誘導体とその製造法 |
JPS56128776A (en) | 1980-03-14 | 1981-10-08 | Otsuka Pharmaceut Factory Inc | Alpha-methylene gamma-butyrolactone derivative |
JPS58199413A (ja) | 1982-05-13 | 1983-11-19 | Pioneer Electronic Corp | デイジタル変調信号の読取装置 |
JPS6058973A (ja) * | 1983-09-13 | 1985-04-05 | Mitsubishi Yuka Yakuhin Kk | γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤 |
JPS6226221A (ja) | 1985-07-29 | 1987-02-04 | Japan Tobacco Inc | 抗変異原性剤 |
JP2524760B2 (ja) | 1987-07-10 | 1996-08-14 | テイカ株式会社 | 新規抗生物質 |
JPH01163175A (ja) | 1987-12-21 | 1989-06-27 | Ss Pharmaceut Co Ltd | フラン−2−オン誘導体 |
US5242945A (en) * | 1991-04-12 | 1993-09-07 | American Home Products Corporation | Tetronic and thiotetronic acid derivatives as phospholipase a2 inhibitors |
US5250735A (en) | 1992-04-03 | 1993-10-05 | University Of Pittsburgh | 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof |
CA2168757A1 (en) * | 1993-09-17 | 1995-03-23 | Robert A. Chrusciel | Substituted tetronic acids useful for treating hiv and other retroviruses |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
ATE201397T1 (de) * | 1994-06-07 | 2001-06-15 | Teijin Ltd | Vitamin d3 derivate und ein verfahren zu ihrer herstellung |
AUPN191295A0 (en) | 1995-03-23 | 1995-04-27 | Unisearch Limited | Microbiocide or microbial regulator |
US5962460A (en) * | 1995-06-27 | 1999-10-05 | National Science Council (Taiwan) | Antineoplastic α-methylene-γ-butyrolactones |
US5646164A (en) * | 1995-11-14 | 1997-07-08 | National Science Council | α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation |
ES2251002T3 (es) | 1995-11-17 | 2006-04-16 | The Johns Hopkins University | Inhibicion de sintasa de acido graso, como medio para reducir la masa adipocita. |
US6222048B1 (en) * | 1995-12-18 | 2001-04-24 | Merck Frosst Canada & Co. | Diaryl-2-(5H)-furanones as Cox-2 inhibitors |
US5618835A (en) | 1996-02-01 | 1997-04-08 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
US6180651B1 (en) * | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
US5981575A (en) * | 1996-11-15 | 1999-11-09 | Johns Hopkins University, The | Inhibition of fatty acid synthase as a means to reduce adipocyte mass |
US5939455A (en) | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
AU6818298A (en) | 1997-04-02 | 1998-10-22 | Merck Frosst Canada & Co. | Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors |
US5905089A (en) * | 1997-04-14 | 1999-05-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of sesquiterpene lactones for treatment of severe inflammatory disorders |
AUPP303498A0 (en) | 1998-04-17 | 1998-05-14 | Unisearch Limited | Inhibition of gram positive bacteria |
AU4428899A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of cyclooxygenase-2 |
WO2000058297A2 (en) | 1999-03-30 | 2000-10-05 | E.I. Du Pont De Nemours And Company | PROCESS FOR THE PREPARATION OF α-METHYLENE LACTONES |
FR2801792B1 (fr) | 1999-12-01 | 2003-04-18 | Sod Conseils Rech Applic | Un nouveau medicament, le dihydromikanolide, son obtention par extraction de la plante mikania micrantha et son utilisation comme agent anti-proliferatif |
US6660511B1 (en) | 2000-03-03 | 2003-12-09 | Rigel Pharmaceuticals, Inc. | Methods of screening for modulation of cell cycle |
US6686390B2 (en) * | 2000-05-22 | 2004-02-03 | Dr. Reddy's Laboratories Limited | Compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them |
JP2002037797A (ja) | 2000-07-25 | 2002-02-06 | Kanegafuchi Chem Ind Co Ltd | マクロファージ選択的細胞死誘導物質 |
AU2002243552C1 (en) | 2001-01-12 | 2006-08-31 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
IL159296A0 (en) | 2001-06-13 | 2004-06-01 | Magnachem Int Lab Inc | Lactone formulations and method of use |
US6686724B2 (en) * | 2002-05-21 | 2004-02-03 | Ford Motor Company | Method of and apparatus for controlling charging and/or discharging of a battery for a hybrid electric vehicle |
US8188145B2 (en) * | 2002-06-12 | 2012-05-29 | Magnachem International Laboratories, Inc. | Synthetic lactone formulations and method of use |
EP1562930A4 (en) * | 2002-11-05 | 2008-12-10 | Magnachem Int Lab Inc | SYNTHETIC LACTONE FORMULATIONS AND METHOD OF USE |
-
2002
- 2002-06-12 IL IL15929602A patent/IL159296A0/xx unknown
- 2002-06-12 AT AT02734779T patent/ATE406367T1/de active
- 2002-06-12 US US10/172,462 patent/US6900242B2/en not_active Expired - Lifetime
- 2002-06-12 RS YU98603A patent/RS52139B/en unknown
- 2002-06-12 AU AU2002306150A patent/AU2002306150B2/en not_active Ceased
- 2002-06-12 EP EP02734779A patent/EP1406895B1/en not_active Expired - Lifetime
- 2002-06-12 DK DK02734779T patent/DK1406895T3/da active
- 2002-06-12 WO PCT/US2002/018602 patent/WO2002100854A1/en active Application Filing
- 2002-06-12 PT PT02734779T patent/PT1406895E/pt unknown
- 2002-06-12 DE DE60228576T patent/DE60228576D1/de not_active Expired - Lifetime
- 2002-06-12 KR KR10-2003-7016356A patent/KR20040030676A/ko active Search and Examination
- 2002-06-12 ES ES02734779T patent/ES2315365T3/es not_active Expired - Lifetime
- 2002-06-12 JP JP2003503621A patent/JP2005500289A/ja active Pending
- 2002-06-12 CA CA2450660A patent/CA2450660C/en not_active Expired - Fee Related
- 2002-06-12 BR BR0210432-6A patent/BR0210432A/pt not_active IP Right Cessation
- 2002-06-12 MX MXPA03011554A patent/MXPA03011554A/es active IP Right Grant
- 2002-06-13 AR ARP020102236A patent/AR036056A1/es not_active Application Discontinuation
- 2002-06-13 UY UY27334A patent/UY27334A1/es not_active Application Discontinuation
-
2003
- 2003-12-10 IL IL159296A patent/IL159296A/en not_active IP Right Cessation
-
2004
- 2004-01-09 CO CO04001331A patent/CO5550429A2/es not_active Application Discontinuation
- 2004-01-12 ZA ZA2004/00208A patent/ZA200400208B/en unknown
-
2005
- 2005-05-26 US US11/139,338 patent/US20050209316A1/en not_active Abandoned
-
2008
- 2008-11-24 CY CY20081101353T patent/CY1108590T1/el unknown
-
2010
- 2010-12-15 US US12/968,508 patent/US8536348B2/en not_active Expired - Fee Related
-
2011
- 2011-03-27 IL IL211958A patent/IL211958A0/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20050209316A1 (en) | 2005-09-22 |
US20110092588A1 (en) | 2011-04-21 |
US8536348B2 (en) | 2013-09-17 |
KR20040030676A (ko) | 2004-04-09 |
ATE406367T1 (de) | 2008-09-15 |
RS98603A (en) | 2006-12-15 |
US6900242B2 (en) | 2005-05-31 |
US20030069393A1 (en) | 2003-04-10 |
JP2005500289A (ja) | 2005-01-06 |
PT1406895E (pt) | 2008-11-04 |
AU2002306150B2 (en) | 2008-02-14 |
CY1108590T1 (el) | 2014-04-09 |
IL211958A0 (en) | 2011-06-30 |
EP1406895A4 (en) | 2004-11-17 |
IL159296A0 (en) | 2004-06-01 |
UY27334A1 (es) | 2003-02-28 |
DK1406895T3 (da) | 2008-12-01 |
CO5550429A2 (es) | 2005-08-31 |
EP1406895B1 (en) | 2008-08-27 |
BR0210432A (pt) | 2004-08-03 |
MXPA03011554A (es) | 2004-10-28 |
WO2002100854A1 (en) | 2002-12-19 |
RS52139B (en) | 2012-08-31 |
EP1406895A1 (en) | 2004-04-14 |
CA2450660A1 (en) | 2002-12-19 |
IL159296A (en) | 2011-06-30 |
ZA200400208B (en) | 2005-06-29 |
DE60228576D1 (de) | 2008-10-09 |
CA2450660C (en) | 2011-08-16 |
ES2315365T3 (es) | 2009-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607817A2 (pt) | processo para a preparação de compostos macrocìclicos | |
CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
HRP20020888B1 (en) | Glycopeptide phosphonate derivatives | |
BRPI0509377A (pt) | compostos de ácido alfa arila ou heteroaril metil beta piperidino propanóico como antagonistas do receptor orl1 | |
DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
RS49906B (sr) | Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova | |
AR022469A1 (es) | Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias | |
BR9407711A (pt) | Composto de ciclopeptídeo processo para preparaçao de um composto de ciclopeptídeo e parasiticida | |
ATE92493T1 (de) | Chinolincarbonsaeurederivate. | |
PA8573501A1 (es) | Derivados de benzoxazina y su empleo | |
PE20221586A1 (es) | Derivados heterociclicos activos como plaguicidas con sustituyentes que contienen azufre | |
AR036176A1 (es) | Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado | |
AR036056A1 (es) | Formulaciones de lactonas y metodos de uso de las mismas | |
CR9499A (es) | Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
HRP20040243B1 (en) | Cross-linked glycopeptide-cephalosporin antibiotics | |
DK1970372T3 (da) | Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler | |
AR045810A1 (es) | 6-[fenil (sustituidas) ] triazolopirimidinas como agentes anticancerosos | |
BR0114424A (pt) | Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação | |
PE20010300A1 (es) | Preparacion de piperidin-4-onas sustituidas | |
ATE113280T1 (de) | Eine perfluoralkylgruppe enthaltende verbindung. | |
BR0215145A (pt) | Compostos de benzotiazina e de benzotiadiazina, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos | |
PT1069132E (pt) | Derivados biciclicos de amino-pirazinonas processo para a sua preparacao e as composicoes farmaceuticas que os contem | |
AR054284A1 (es) | Procedimiento para la preparacion de sales de acido sulfonico de oxabispidinas | |
AR038260A1 (es) | Compuestos derivados de benzotiazina y de benzotiazidina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |